echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Pfizer pulled out and stopped seeking to buy Shishi Shiguibo

    Pfizer pulled out and stopped seeking to buy Shishi Shiguibo

    • Last Update: 2021-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The industry has long been rumoured that BMY, the pharmaceutical giant, is going to be acquired, and if that's true, there's one company that has the power but won't make a bid, and that's Pfizer (PFE).
    blog on Barron' investment website explains why Pfizer is unlikely to bid. The blog quoted Deutsche Bank's Greg Gilbert and Esther Rajavel as commenting on StreetInsider, noting that Pfizer would not bid because such a deal "would be a huge opportunity/risk for the immune oncology sector (market value $90 billion plus premium), which is fraught with short-term uncertainty and which Pfizer has deployed at least in part." Two analysts said Pfizer would prefer to look for "more diversified value dynamics" and "cost-effective projects" if it were to invest heavily in such a large company
    BioSpace reported earlier this week that at least four large-cap companies were said to be interested in buying PepsiCo, including Pfizer. But if Pfizer is ruled out, three companies, GILD, Novart (NVS) and Switzerland's RHHBY, could bid.
    has lost more than 15 per cent of its shares since January 10 and is now valued at about $50bn. Earlier this month, the company lowered its profit forecast for 2017. Although the loss of market share is not small, hundred-time Meishi Guibao asking price will be relatively high. Analysts at Deutsche Bank suggested $90m, but some forecast the company could sell for as much as $120m.
    the rumors have been hot, but the board of directors of Shishi Shiguibao has not expressed its willingness to accept any offer.
    , according to a recent Bloomberg report, The Times has dropped from fourth to ninth place on america's most valuable list. That's largely because last year's failure of its main PD-1 inhibitor, Opdivo, hit the company hard. In August 2016, the Phase III clinical data released by Shishi Shiguibao showed that Opdivo failed to reach the trial point of PD-L1 expression of no progress in lung cancer patients. The defeat created a good opportunity for rival MERCK's PD-1 inhibitor Keytruda to grab market share. The company is concerned that Keytruda will be approved as a first-line treatment for lung cancer. As a result of Merck's success, the company is not counting on the Food and Drug Administration's rapid approval of the Optivo portfolio, but some analysts say it suggests the data is questionable.
    Opdivo not only faces the threat of Keytruda competing for market share, but Roche's Tecentriq took 10 percent of the market from Opdivo in the fourth quarter of 2016. (Health)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.